• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.

    8/15/25 12:26:27 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IRWD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    IRONWOOD PHARMACEUTICALS INC

    (Name of Issuer)


    Class A common stock, $0.001 par value

    (Title of Class of Securities)


    23254X201

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    23254X201


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    16,150,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    16,150,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    16,150,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.94 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    23254X201


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    16,150,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    16,150,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    16,150,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.94 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IRONWOOD PHARMACEUTICALS INC
    (b)Address of issuer's principal executive offices:

    9,468,000 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    Class A common stock, $0.001 par value
    (e)CUSIP No.:

    23254X201
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    16,150,000
    (b)Percent of class:

    9.94  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    16,150,000

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    16,150,000 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on 162,434,130 Shares outstanding as of July 31, 2025, as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:08/15/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:08/15/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 15, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $IRWD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRWD

    DatePrice TargetRatingAnalyst
    4/15/2025Overweight → Equal Weight
    Wells Fargo
    4/15/2025Buy → Hold
    Jefferies
    4/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    9/9/2024$5.00Market Perform
    Leerink Partners
    8/8/2024$12.00 → $4.00Overweight → Equal Weight
    CapitalOne
    1/17/2024$21.00Buy
    Craig Hallum
    12/14/2023$20.00Overweight
    Wells Fargo
    11/9/2023$21.00Buy
    Jefferies
    More analyst ratings

    $IRWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Gaskins Tammi L sold $1,105 worth of shares (1,316 units at $0.84), decreasing direct ownership by 0.54% to 241,280 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    8/13/25 4:05:09 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer John Minardo sold $6,513 worth of shares (7,754 units at $0.84), decreasing direct ownership by 2% to 400,378 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    8/13/25 4:05:08 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Martini Gregory S. sold $1,063 worth of shares (1,265 units at $0.84), decreasing direct ownership by 0.69% to 182,545 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    8/13/25 4:05:05 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

    – LINZESS® (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – – Plans to align with FDA on confirmatory Phase 3 trial design in Q4 2025 – – Progressing previously announced strategic alternatives review to maximize shareholder value – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. "In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand growth of 10% year-over-year. Additiona

    8/7/25 7:05:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharmaceuticals Reports First Quarter 2025 Results

    – On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line with full-year expectations – – Exploring strategic alternatives to maximize stockholder value – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. "LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently

    5/7/25 7:05:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing

    4/30/25 4:25:00 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ironwood Pharma downgraded by Wells Fargo

    Wells Fargo downgraded Ironwood Pharma from Overweight to Equal Weight

    4/15/25 9:27:22 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharma downgraded by Jefferies

    Jefferies downgraded Ironwood Pharma from Buy to Hold

    4/15/25 9:27:01 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharma downgraded by Citizens JMP

    Citizens JMP downgraded Ironwood Pharma from Mkt Outperform to Mkt Perform

    4/14/25 11:37:23 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRWD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ironwood Pharmaceuticals Inc.

    SCHEDULE 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    8/15/25 12:26:27 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ironwood Pharmaceuticals Inc.

    SCHEDULE 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    8/12/25 5:58:24 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Ironwood Pharmaceuticals Inc.

    10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

    8/11/25 4:13:45 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Duane Jon R bought $60,204 worth of shares (6,920 units at $8.70), increasing direct ownership by 6% to 121,028 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    3/8/24 4:05:19 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emany Sravan Kumar bought $100,216 worth of shares (10,684 units at $9.38), increasing direct ownership by 4% to 301,733 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    3/6/24 4:05:12 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Emany Sravan Kumar bought $300,119 worth of shares (36,072 units at $8.32), increasing direct ownership by 24% to 188,730 units

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    9/18/23 5:07:12 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ironwood Pharmaceuticals Inc.

    SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    11/14/24 3:31:33 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

    SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    11/12/24 3:47:50 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ironwood Pharmaceuticals Inc.

    SC 13G/A - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    11/4/24 11:46:39 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRWD
    Leadership Updates

    Live Leadership Updates

    View All

    Millrose Properties Set to Join S&P SmallCap 600

    NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE:MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE:LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. Following the spin-off, Lennar will remain in the S&P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to

    2/5/25 6:28:00 PM ET
    $IRWD
    $LEN
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Homebuilding
    Consumer Discretionary

    Memo Therapeutics AG appoints Paul Carter as Chairperson

    PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

    7/8/24 7:00:00 AM ET
    $IMTX
    $IRWD
    $VECT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he

    12/1/21 7:30:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IRWD
    Financials

    Live finance-specific insights

    View All

    Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

    – Announced positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time – – Initiated rolling NDA submission; on track to be completed in Q3 2025 – – LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year – – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results

    2/27/25 7:00:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, February 27, 2025, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, March

    2/20/25 4:00:00 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

    – Data from open label extension study of apraglutide demonstrate further increase in patients achieving enteral autonomy – – Initiated rolling NDA submission, now to include long-term extension data given continued clinical improvement over time, with submission completion expected in Q3 2025 – – Organizational restructuring positions the Company to realize the potential of apraglutide in SBS and long-term success in GI and rare disease – – Expects adjusted EBITDA excluding stock-based compensation of greater than $85 million in 2025, driven by strong LINZESS prescription demand growth and expense management to offset pricing headwinds – - Greg Martini named Chief Financial Officer

    1/29/25 4:05:00 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care